These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22738800)

  • 21. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
    World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum DLK1 is a potential prognostic biomarker in patients with hepatocellular carcinoma.
    Li H; Cui ML; Chen TY; Xie HY; Cui Y; Tu H; Chen FH; Ge C; Li JJ
    Tumour Biol; 2015 Nov; 36(11):8399-404. PubMed ID: 26018510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients.
    Mashaly AH; Anwar R; Ebrahim MA; Eissa LA; El Shishtawy MM
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1503-1508. PubMed ID: 29936723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma.
    Fartoux L; Decaens T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S21-30. PubMed ID: 21742297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma.
    Matsuzaki Y; Osuga T; Chiba T; Saito Y; Tanaka N; Itai Y; Tsujii H
    Intern Med; 1995 Apr; 34(4):302-4. PubMed ID: 7606109
    [No Abstract]   [Full Text] [Related]  

  • 26. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma.
    Lu Y; Li N; Gao L; Xu YJ; Huang C; Yu K; Ling Q; Cheng Q; Chen S; Zhu M; Fang J; Chen M; Ong CN
    Cancer Res; 2016 May; 76(10):2912-20. PubMed ID: 26976432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Early diagnosis of hepatocellular carcinoma].
    Hirooka N; Matsuura N; Ohto M
    Nihon Rinsho; 1994 Jan; 52(1):69-74. PubMed ID: 7509420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma: clinical features, evaluation and treatment.
    Khurshid H; Malik IA
    J Pak Med Assoc; 1995 May; 45(5):136-43. PubMed ID: 7563580
    [No Abstract]   [Full Text] [Related]  

  • 29. Dickkopf-1: as a diagnostic and prognostic serum marker for early hepatocellular carcinoma.
    Yang H; Chen GD; Fang F; Liu Z; Lau SH; Zhang JF; Lau WY; Yang LY
    Int J Biol Markers; 2013 Sep; 28(3):286-97. PubMed ID: 23568769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers for Hepatocellular Carcinoma (HCC): An Update.
    Li D; Satomura S
    Adv Exp Med Biol; 2015; 867():179-93. PubMed ID: 26530367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for hepatocellular carcinoma.
    Roberts LR
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):223-34. PubMed ID: 27166603
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
    Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
    Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.
    Li J; Cheng ZJ; Liu Y; Yan ZL; Wang K; Wu D; Wan XY; Xia Y; Lau WY; Wu MC; Shen F
    Oncotarget; 2015 Apr; 6(11):9551-63. PubMed ID: 25871387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma.
    Johnson PJ
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):452-454. PubMed ID: 28749905
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma.
    He J; Liu Y
    EBioMedicine; 2016 Oct; 12():4-5. PubMed ID: 27665049
    [No Abstract]   [Full Text] [Related]  

  • 36. Magnetic resonance imaging characterization of hepatocellular carcinoma expressing progenitor cell markers.
    Ward SC; Rosen A
    Liver Int; 2012 Mar; 32(3):349-51. PubMed ID: 22309102
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous regression of hepatocellular carcinoma.
    Kondo S; Okusaka T; Ueno H; Ikeda M; Morizane C
    Int J Clin Oncol; 2006 Oct; 11(5):407-11. PubMed ID: 17058140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. History and recent progress in evaluation of the fucosylated alpha-fetoprotein fraction.
    Aoyagi Y; Tamura Y; Suda T
    J Gastroenterol Hepatol; 2011 Apr; 26(4):615-6. PubMed ID: 21418297
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma.
    Jia X; Gao Y; Zhai D; Liu J; Cai J; Wang Y; Jing L; Du Z
    Technol Cancer Res Treat; 2016 Dec; 15(6):780-786. PubMed ID: 26370140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.